175 related articles for article (PubMed ID: 15681065)
1. Adenovirus immunoregulatory E3 proteins prolong transplants of human cells in immunocompetent mice.
Toth K; Doronin K; Kuppuswamy M; Ward P; Tollefson AE; Wold WS
Virus Res; 2005 Mar; 108(1-2):149-59. PubMed ID: 15681065
[TBL] [Abstract][Full Text] [Related]
2. Heterologous expression of adenovirus E3-gp19K in an E1a-deleted adenovirus vector inhibits MHC I expression in vitro, but does not prolong transgene expression in vivo.
Schowalter DB; Tubb JC; Liu M; Wilson CB; Kay MA
Gene Ther; 1997 Apr; 4(4):351-60. PubMed ID: 9176522
[TBL] [Abstract][Full Text] [Related]
3. The constitutive expression of the immunomodulatory gp19k protein in E1-, E3- adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector.
Lee MG; Abina MA; Haddada H; Perricaudet M
Gene Ther; 1995 Jun; 2(4):256-62. PubMed ID: 7552985
[TBL] [Abstract][Full Text] [Related]
4. Deletion of the E3-6.7K/gp19K region reduces the persistence of wild-type adenovirus in a permissive tumor model in Syrian hamsters.
Bortolanza S; Bunuales M; Alzuguren P; Lamas O; Aldabe R; Prieto J; Hernandez-Alcoceba R
Cancer Gene Ther; 2009 Sep; 16(9):703-12. PubMed ID: 19229289
[TBL] [Abstract][Full Text] [Related]
5. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement.
Ji L; Bouvet M; Price RE; Roth JA; Fang B
Gene Ther; 1999 Mar; 6(3):393-402. PubMed ID: 10435089
[TBL] [Abstract][Full Text] [Related]
6. Association of vaccinia virus-expressed adenovirus E3-19K glycoprotein with class I MHC and its effects on virulence in a murine pneumonia model.
Grunhaus A; Cho S; Horwitz MS
Virology; 1994 May; 200(2):535-46. PubMed ID: 8178441
[TBL] [Abstract][Full Text] [Related]
7. Generation and characterization of E1/E2a/E3/E4-deficient adenoviral vectors encoding human factor VIII.
Andrews JL; Kadan MJ; Gorziglia MI; Kaleko M; Connelly S
Mol Ther; 2001 Mar; 3(3):329-36. PubMed ID: 11273775
[TBL] [Abstract][Full Text] [Related]
8. The E3-11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants.
Tollefson AE; Ryerse JS; Scaria A; Hermiston TW; Wold WS
Virology; 1996 Jun; 220(1):152-62. PubMed ID: 8659107
[TBL] [Abstract][Full Text] [Related]
9. Mouse anti-adenovirus cytotoxic T lymphocytes. Inhibition of lysis by E3 gp19K but not E3 14.7K.
Rawle FC; Tollefson AE; Wold WS; Gooding LR
J Immunol; 1989 Sep; 143(6):2031-7. PubMed ID: 2789254
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus region E3 proteins that prevent cytolysis by cytotoxic T cells and tumor necrosis factor.
Wold WS; Gooding LR
Mol Biol Med; 1989 Oct; 6(5):433-52. PubMed ID: 2533958
[TBL] [Abstract][Full Text] [Related]
11. The signal-anchor domain of adenovirus E3-6.7K, a type III integral membrane protein, can direct adenovirus E3-gp19K, a type I integral membrane protein, into the membrane of the endoplasmic reticulum.
Wilson-Rawls J; Deutscher SL; Wold WS
Virology; 1994 May; 201(1):66-76. PubMed ID: 8178490
[TBL] [Abstract][Full Text] [Related]
12. Sequence and functional analysis of the human adenovirus type 7 E3-gp19K protein from 17 clinical isolates.
Hermiston TW; Hellwig R; Hierholzer JC; Wold WS
Virology; 1993 Dec; 197(2):593-600. PubMed ID: 8249282
[TBL] [Abstract][Full Text] [Related]
13. Resistance of human cells to the adenovirus E3 effect on class I MHC antigen expression. Implications for antiviral immunity.
Routes JM; Cook JL
J Immunol; 1990 Apr; 144(7):2763-70. PubMed ID: 2156934
[TBL] [Abstract][Full Text] [Related]
14. E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models.
Wang Y; Hallden G; Hill R; Anand A; Liu TC; Francis J; Brooks G; Lemoine N; Kirn D
Nat Biotechnol; 2003 Nov; 21(11):1328-35. PubMed ID: 14555956
[TBL] [Abstract][Full Text] [Related]
15. Optimization of adenovirus serotype 35 vectors for efficient transduction in human hematopoietic progenitors: comparison of promoter activities.
Sakurai F; Kawabata K; Yamaguchi T; Hayakawa T; Mizuguchi H
Gene Ther; 2005 Oct; 12(19):1424-33. PubMed ID: 15944730
[TBL] [Abstract][Full Text] [Related]
16. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice.
Fields PA; Armstrong E; Hagstrom JN; Arruda VR; Murphy ML; Farrell JP; High KA; Herzog RW
Gene Ther; 2001 Mar; 8(5):354-61. PubMed ID: 11313811
[TBL] [Abstract][Full Text] [Related]
17. Expression of adenovirus E3/19K protein does not alter mouse MHC class I-restricted responses to vaccinia virus.
Cox JH; Buller RM; Bennink JR; Yewdell JW; Karupiah G
Virology; 1994 Nov; 204(2):558-62. PubMed ID: 7941322
[TBL] [Abstract][Full Text] [Related]
18. Subgroup B adenovirus type 35 early region 3 mRNAs differ from those of the subgroup C adenoviruses.
Basler CF; Horwitz MS
Virology; 1996 Jan; 215(2):165-77. PubMed ID: 8560763
[TBL] [Abstract][Full Text] [Related]
19. Noninvasive visualization of adenovirus replication with a fluorescent reporter in the E3 region.
Ono HA; Le LP; Davydova JG; Gavrikova T; Yamamoto M
Cancer Res; 2005 Nov; 65(22):10154-8. PubMed ID: 16287998
[TBL] [Abstract][Full Text] [Related]
20. Construction and characterization of E1-minus replication-defective adenovirus vectors that express E3 proteins from the E1 region.
Toth K; Kuppuswamy M; Doronin K; Doronina O; Lichtenstein D; Tollefson A; Wold W
Virology; 2002 Sep; 301(1):99-108. PubMed ID: 12359450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
